ANTIMICROBIAL RESISTANCE PARTERN OF PATHOGENS CAUSING VENTILATOR ASSOCIATED PNEUMONIA IN NATIONAL HOSPITAL FOR TROPICAL DISEASES
Main Article Content
Abstract
High burden of ventilator associated pneumonia (VAP) in Intensive Care Units results from multidrug resistance of pathogens.
Objectives: To identify common pathogens as well as their antibiograms to building empiric therapy for VAP.
Methods: A cross-sectional survey was carried out pathogens of VAP, diagnosed VAP according to CDC criteria, in Intensive Care Center at National Hospital for Tropical Diseases from 5/2023 – 4/2025.
Results: There were 90 patients included with mean age of 68.7 ± 15,3 years, 83.0% was male, 60.0% having at least one comorbidity. Most common indications for invasive mechanical ventilation were pneumonia, sepsis and septic shock. Gram negative bacteria accounted for 99% VAP pathogens. Acinetobacter spp. was the most common pathogen accounted for 58.2%, Klebsiella spp. 19,4% and P. aeruginosa 14,6% with carbapenem resistance accounted for 100%, 85.0% and 80.0%, respectively. Especially, there was one strain of Klebsiella spp and one isolated P. aeruginosa showed resistant to colistin.
Conclusions: The most prominent pathogens of VAP were Acinetobacter spp., Klebsiella spp. and P. aeruginosa with high ratio of carbapenem resistance and serious risk alarm with appearance of colistin resistance.
Article Details
Keywords
Ventilator associated pneumonia, ventilator associated pneumonia pathogen, resistant to new beta-lactam, colistin resistance.
References
[2] Nhu NTK, Lan NPH, Campbell JI, et al. (2014). Emergence of carbapenem-resistant Acinetobacter baumannii as the major cause of ventilator-associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. Journal of Medical Microbiology; 63(10):1386-1394. doi:10.1099/jmm.0.076646-0.
[3] CDC. (2025). Ventilator-associated Event (VAE). Published online 2025. https://www.cdc.gov/nhsn/PDFs/pscManual/10-VAE_FINAL.pdf.
[4] Chang Y, Jeon K, Lee SM, et al. (2021). The Distribution of Multidrug-resistant Microorganisms and Treatment Status of Hospital-acquired Pneumonia/Ventilator-associated Pneumonia in Adult Intensive Care Units: a Prospective Cohort Observational Study. Journal of Korean Medical Science; 36(41). doi:10.3346/jkms.2021.36.e251.
[5] Hurley JC. (2016). World-wide variation in incidence of Acinetobacter associated ventilator associated pneumonia: a meta-regression. BMC Infectious Diseases; 16(1):577. doi:10.1186/s12879-016-1921-4.
[6] Vo TPM, Dinh TC, Phan HV, et al. (2022). Ventilator-Associated Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Vietnam: Antibiotic Resistance, Treatment Outcomes, and Colistin-Associated Adverse Effects. Healthcare; 10(9):1765. doi:10.3390/healthcare10091765.
[7] Pfaller MA, Shortridge D, Harris KA, et al. (2021). Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018. Int J Infect Dis; 112:321-326. doi:10.1016/j.ijid.2021.09.064.
[8] Khunkit P, Siripaitoon P, Lertsrisatit Y, et al. (2024). Impact of Empirical Antimicrobial Treatment on Patients with Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia. Antibiotics; 13(8):729. doi:10.3390/antibiotics13080729.